Bakkal Temi Yasemin, Yılmaz Tuğan Büşra, Çıtakkul İlkay, Baydar Ece, Karaca Gözde, Balcı Sibel, Çabuk Devrim, Kefeli Umut, Yüksel Nurşen, Uygun Kazım
Department of Internal Medicine and Medical Oncology, Faculty of Medicine, Kocaeli University, 41001 Kocaeli, Turkey.
Department of Ophthalmology, Faculty of Medicine, Kocaeli University, 41001 Kocaeli, Turkey.
Diagnostics (Basel). 2025 Jul 1;15(13):1682. doi: 10.3390/diagnostics15131682.
To conduct a comparative analysis of layer-by-layer macular thickness, peripapillary retinal nerve fiber layer (pRNFL), and minimum rim width (MRW) between the eyes of patients with prostate cancer undergoing treatment with androgen receptor pathway inhibitors (ARPIs) and those of age- and sex-matched healthy controls, with the aim of assessing the potential effects of ARPIs on retinal structure. In this prospective cross-sectional study, 80 eyes of 80 patients with ARPI-treated metastatic prostate cancer and 80 eyes of 80 age-matched healthy controls were evaluated using Heidelberg Spectralis optical coherence tomography (OCT). Layer-by-layer macular thickness, pRNFL, and MRW were measured and compared between groups. Thickness in most segments of retinal layers and pRNFL, as well as all MRW values, were significantly lower in the ARPI-treated group than in the controls ( < 0.05). No significant differences were observed between groups in terms of age, visual acuity, intraocular pressure, central corneal thickness, or lens status. This study is the first to evaluate layer-by-layer macular thickness in patients with metastatic prostate cancer treated with ARPIs, revealing significant thinning in nearly all macular layers, pRNFL, and MRW. These findings suggest that ARPI therapy may induce neurodegenerative changes in retinal and optic nerve structures. Therefore, further research is warranted to assess the ocular safety of these therapeutic agents.
对接受雄激素受体通路抑制剂（ARPI）治疗的前列腺癌患者与年龄和性别匹配的健康对照者的双眼进行黄斑层厚度、视乳头周围视网膜神经纤维层（pRNFL）和最小视盘边缘宽度（MRW）的比较分析，以评估ARPI对视网膜结构的潜在影响。在这项前瞻性横断面研究中，使用海德堡Spectralis光学相干断层扫描（OCT）对80例接受ARPI治疗的转移性前列腺癌患者的80只眼和80例年龄匹配的健康对照者的80只眼进行了评估。测量并比较了两组之间的黄斑层厚度、pRNFL和MRW。ARPI治疗组视网膜各层和pRNFL的大多数节段的厚度以及所有MRW值均显著低于对照组（<0.05）。两组在年龄、视力、眼压、中央角膜厚度或晶状体状态方面未观察到显著差异。本研究首次评估了接受ARPI治疗的转移性前列腺癌患者的黄斑层厚度，发现几乎所有黄斑层、pRNFL和MRW均显著变薄。这些发现表明，ARPI治疗可能会引起视网膜和视神经结构的神经退行性改变。因此，有必要进一步研究以评估这些治疗药物的眼部安全性。
